Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies
- PMID: 7907208
- DOI: 10.1002/ana.410350310
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies
Abstract
Taxol is a novel antineoplastic agent that has demonstrated impressive clinical activity in breast, ovarian, lung, and head and neck cancers. This broad antitumor activity of taxol in cisplatin-sensitive tumors suggests that the combination of taxol and cisplatin may become one of the most commonly used taxol-based chemotherapeutic regimen in the treatment of solid tumors. Both taxol and cisplatin, however, are neurotoxic. To study the neurotoxic effects of these two agents when used in combination, we prospectively evaluated neurological function at baseline, during, and following treatment, in 21 cancer patients treated with taxol (135-350 mg/m2), cisplatin (75-100 mg/m2), and granulocyte-colony stimulating factor (5 micrograms/kg). Twenty of the 21 patients (95%) developed a sensory-motor neuropathy 1 to 21 weeks after the initiation of therapy, that was progressive with each additional course of chemotherapy. The neuropathy was symmetrical, length dependent, axonal in nature by physiological studies, and more pronounced in those patients who received higher doses of taxol. The neuropathy appeared earlier and at lower taxol doses in those patients with preexisting neuropathies. We conclude that sensory-motor neuropathy is a frequent dose-dependent toxicity of combined cisplatin and taxol use. Peripheral neuropathy is likely to become the major dose-limiting toxicity of taxol-cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte-colony stimulating factor.
Similar articles
-
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.Semin Oncol. 1995 Dec;22(6 Suppl 15):50-4. Semin Oncol. 1995. PMID: 8643971 Clinical Trial.
-
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.Semin Oncol. 1995 Dec;22(6 Suppl 15):29-33. Semin Oncol. 1995. PMID: 8643967 Clinical Trial.
-
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22. Semin Oncol. 1996. PMID: 8893894 Clinical Trial.
-
Neurotoxicity of Taxol.J Natl Cancer Inst Monogr. 1993;(15):107-15. J Natl Cancer Inst Monogr. 1993. PMID: 7912516 Review.
-
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].Gan To Kagaku Ryoho. 1998 Mar;25(4):605-15. Gan To Kagaku Ryoho. 1998. PMID: 9530372 Review. Japanese.
Cited by
-
MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.Brain Behav Immun. 2015 Oct;49:255-66. doi: 10.1016/j.bbi.2015.06.003. Epub 2015 Jun 9. Brain Behav Immun. 2015. PMID: 26065826 Free PMC article.
-
Bibliometric Analysis Reveals a 20-Year Research Trend for Chemotherapy-Induced Peripheral Neuropathy.Front Neurol. 2022 Feb 8;12:793663. doi: 10.3389/fneur.2021.793663. eCollection 2021. Front Neurol. 2022. PMID: 35211075 Free PMC article.
-
Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.J Neurol. 2012 Sep;259(9):1936-43. doi: 10.1007/s00415-012-6442-5. Epub 2012 Feb 17. J Neurol. 2012. PMID: 22349867
-
Barriers to pain assessment and management in cancer survivorship.J Cancer Surviv. 2008 Mar;2(1):65-71. doi: 10.1007/s11764-008-0047-0. Epub 2008 Feb 15. J Cancer Surviv. 2008. PMID: 18648988 Free PMC article.
-
The test-retest reliability of the H-Reflex and swaymeter in women aged 30-65 years.PLoS One. 2025 Jun 23;20(6):e0314437. doi: 10.1371/journal.pone.0314437. eCollection 2025. PLoS One. 2025. PMID: 40549812 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical